Panel 6

Vaccines

Stephen I. Pelton, Melinda M. Pettigrew, Stephen J. Barenkamp, Fabrice Godfroid, Carlos G. Grijalva, Amanda Leach, Janak Patel, Timothy F. Murphy, Sanja Selak, Lauren O. Bakaletz

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective. To update progress on the effectiveness of vaccine for prevention of acute otitis media (AOM) and identification of promising candidate antigens against Streptococcus pneumoniae, nontypeable Haemophilus influenzae, and Moraxella catarrhalis. Review Methods. Literature searches were performed in OvidSP and PubMed restricted to articles published between June 2007 and September 2011. Search terms included otitis media, vaccines, vaccine antigens, and each of the otitis pathogens and candidate antigens identified in the ninth conference report. Conclusions. The current report provides further evidence for the effectiveness of pneumococcal conjugate vaccines (PCVs) in the prevention of otitis media. Observational studies demonstrate a greater decline in AOM episodes than reported in clinical efficacy trials. Unmet challenges include extending protection to additional serotypes and additional pathogens, the need to prevent early episodes, the development of correlates of protection for protein antigens, and the need to define where an otitis media vaccine strategy fits with priorities for child health. Implications for Practice. Acute otitis media continues to be a burden on children and families, especially those who suffer from frequent recurrences. The 7-valent PCV (PCV7) has reduced the burden of disease as well as shifted the pneumococcal serotypes and the distribution of otopathogens currently reported in children with AOM. Antibiotic resistance remains an ongoing challenge. Multiple candidate antigens have demonstrated the necessary requirements of conservation, surface exposure, immunogenicity, and protection in animal models. Further research on the role of each antigen in pathogenesis, in the development of correlates of protection in animal models, and in new adjuvants to elicit responses in the youngest infants is likely to be productive and permit more antigens to move into human clinical trials.

Original languageEnglish (US)
JournalOtolaryngology - Head and Neck Surgery (United States)
Volume148
Issue number4 SUPPL.
DOIs
StatePublished - Apr 2013

Fingerprint

Otitis Media
Vaccines
Antigens
Conjugate Vaccines
Pneumococcal Vaccines
Animal Models
Clinical Trials
Moraxella (Branhamella) catarrhalis
Otitis
Haemophilus influenzae
Microbial Drug Resistance
Streptococcus pneumoniae
PubMed
Observational Studies
Recurrence
Research
Proteins

Keywords

  • Candidate antigens
  • Otitis media
  • Otitis pathogens
  • Vaccine antigens
  • Vaccines

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Surgery
  • Medicine(all)

Cite this

Pelton, S. I., Pettigrew, M. M., Barenkamp, S. J., Godfroid, F., Grijalva, C. G., Leach, A., ... Bakaletz, L. O. (2013). Panel 6: Vaccines. Otolaryngology - Head and Neck Surgery (United States), 148(4 SUPPL.). https://doi.org/10.1177/0194599812466535

Panel 6 : Vaccines. / Pelton, Stephen I.; Pettigrew, Melinda M.; Barenkamp, Stephen J.; Godfroid, Fabrice; Grijalva, Carlos G.; Leach, Amanda; Patel, Janak; Murphy, Timothy F.; Selak, Sanja; Bakaletz, Lauren O.

In: Otolaryngology - Head and Neck Surgery (United States), Vol. 148, No. 4 SUPPL., 04.2013.

Research output: Contribution to journalArticle

Pelton, SI, Pettigrew, MM, Barenkamp, SJ, Godfroid, F, Grijalva, CG, Leach, A, Patel, J, Murphy, TF, Selak, S & Bakaletz, LO 2013, 'Panel 6: Vaccines', Otolaryngology - Head and Neck Surgery (United States), vol. 148, no. 4 SUPPL.. https://doi.org/10.1177/0194599812466535
Pelton SI, Pettigrew MM, Barenkamp SJ, Godfroid F, Grijalva CG, Leach A et al. Panel 6: Vaccines. Otolaryngology - Head and Neck Surgery (United States). 2013 Apr;148(4 SUPPL.). https://doi.org/10.1177/0194599812466535
Pelton, Stephen I. ; Pettigrew, Melinda M. ; Barenkamp, Stephen J. ; Godfroid, Fabrice ; Grijalva, Carlos G. ; Leach, Amanda ; Patel, Janak ; Murphy, Timothy F. ; Selak, Sanja ; Bakaletz, Lauren O. / Panel 6 : Vaccines. In: Otolaryngology - Head and Neck Surgery (United States). 2013 ; Vol. 148, No. 4 SUPPL.
@article{c9d745b8d2c14ed1bde49b46a591e297,
title = "Panel 6: Vaccines",
abstract = "Objective. To update progress on the effectiveness of vaccine for prevention of acute otitis media (AOM) and identification of promising candidate antigens against Streptococcus pneumoniae, nontypeable Haemophilus influenzae, and Moraxella catarrhalis. Review Methods. Literature searches were performed in OvidSP and PubMed restricted to articles published between June 2007 and September 2011. Search terms included otitis media, vaccines, vaccine antigens, and each of the otitis pathogens and candidate antigens identified in the ninth conference report. Conclusions. The current report provides further evidence for the effectiveness of pneumococcal conjugate vaccines (PCVs) in the prevention of otitis media. Observational studies demonstrate a greater decline in AOM episodes than reported in clinical efficacy trials. Unmet challenges include extending protection to additional serotypes and additional pathogens, the need to prevent early episodes, the development of correlates of protection for protein antigens, and the need to define where an otitis media vaccine strategy fits with priorities for child health. Implications for Practice. Acute otitis media continues to be a burden on children and families, especially those who suffer from frequent recurrences. The 7-valent PCV (PCV7) has reduced the burden of disease as well as shifted the pneumococcal serotypes and the distribution of otopathogens currently reported in children with AOM. Antibiotic resistance remains an ongoing challenge. Multiple candidate antigens have demonstrated the necessary requirements of conservation, surface exposure, immunogenicity, and protection in animal models. Further research on the role of each antigen in pathogenesis, in the development of correlates of protection in animal models, and in new adjuvants to elicit responses in the youngest infants is likely to be productive and permit more antigens to move into human clinical trials.",
keywords = "Candidate antigens, Otitis media, Otitis pathogens, Vaccine antigens, Vaccines",
author = "Pelton, {Stephen I.} and Pettigrew, {Melinda M.} and Barenkamp, {Stephen J.} and Fabrice Godfroid and Grijalva, {Carlos G.} and Amanda Leach and Janak Patel and Murphy, {Timothy F.} and Sanja Selak and Bakaletz, {Lauren O.}",
year = "2013",
month = "4",
doi = "10.1177/0194599812466535",
language = "English (US)",
volume = "148",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Panel 6

T2 - Vaccines

AU - Pelton, Stephen I.

AU - Pettigrew, Melinda M.

AU - Barenkamp, Stephen J.

AU - Godfroid, Fabrice

AU - Grijalva, Carlos G.

AU - Leach, Amanda

AU - Patel, Janak

AU - Murphy, Timothy F.

AU - Selak, Sanja

AU - Bakaletz, Lauren O.

PY - 2013/4

Y1 - 2013/4

N2 - Objective. To update progress on the effectiveness of vaccine for prevention of acute otitis media (AOM) and identification of promising candidate antigens against Streptococcus pneumoniae, nontypeable Haemophilus influenzae, and Moraxella catarrhalis. Review Methods. Literature searches were performed in OvidSP and PubMed restricted to articles published between June 2007 and September 2011. Search terms included otitis media, vaccines, vaccine antigens, and each of the otitis pathogens and candidate antigens identified in the ninth conference report. Conclusions. The current report provides further evidence for the effectiveness of pneumococcal conjugate vaccines (PCVs) in the prevention of otitis media. Observational studies demonstrate a greater decline in AOM episodes than reported in clinical efficacy trials. Unmet challenges include extending protection to additional serotypes and additional pathogens, the need to prevent early episodes, the development of correlates of protection for protein antigens, and the need to define where an otitis media vaccine strategy fits with priorities for child health. Implications for Practice. Acute otitis media continues to be a burden on children and families, especially those who suffer from frequent recurrences. The 7-valent PCV (PCV7) has reduced the burden of disease as well as shifted the pneumococcal serotypes and the distribution of otopathogens currently reported in children with AOM. Antibiotic resistance remains an ongoing challenge. Multiple candidate antigens have demonstrated the necessary requirements of conservation, surface exposure, immunogenicity, and protection in animal models. Further research on the role of each antigen in pathogenesis, in the development of correlates of protection in animal models, and in new adjuvants to elicit responses in the youngest infants is likely to be productive and permit more antigens to move into human clinical trials.

AB - Objective. To update progress on the effectiveness of vaccine for prevention of acute otitis media (AOM) and identification of promising candidate antigens against Streptococcus pneumoniae, nontypeable Haemophilus influenzae, and Moraxella catarrhalis. Review Methods. Literature searches were performed in OvidSP and PubMed restricted to articles published between June 2007 and September 2011. Search terms included otitis media, vaccines, vaccine antigens, and each of the otitis pathogens and candidate antigens identified in the ninth conference report. Conclusions. The current report provides further evidence for the effectiveness of pneumococcal conjugate vaccines (PCVs) in the prevention of otitis media. Observational studies demonstrate a greater decline in AOM episodes than reported in clinical efficacy trials. Unmet challenges include extending protection to additional serotypes and additional pathogens, the need to prevent early episodes, the development of correlates of protection for protein antigens, and the need to define where an otitis media vaccine strategy fits with priorities for child health. Implications for Practice. Acute otitis media continues to be a burden on children and families, especially those who suffer from frequent recurrences. The 7-valent PCV (PCV7) has reduced the burden of disease as well as shifted the pneumococcal serotypes and the distribution of otopathogens currently reported in children with AOM. Antibiotic resistance remains an ongoing challenge. Multiple candidate antigens have demonstrated the necessary requirements of conservation, surface exposure, immunogenicity, and protection in animal models. Further research on the role of each antigen in pathogenesis, in the development of correlates of protection in animal models, and in new adjuvants to elicit responses in the youngest infants is likely to be productive and permit more antigens to move into human clinical trials.

KW - Candidate antigens

KW - Otitis media

KW - Otitis pathogens

KW - Vaccine antigens

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=84878841822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878841822&partnerID=8YFLogxK

U2 - 10.1177/0194599812466535

DO - 10.1177/0194599812466535

M3 - Article

VL - 148

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 4 SUPPL.

ER -